Haselmeier Establishes Haselmeier Inc. in the United States
News Apr 23, 2013
The US is a logical step in our global expansion, say Haselmeier officials, the United States is the largest healthcare market and home to many leading pharmaceutical and biotech companies.
"With the increasing interest in self-injection technology in the US, it is important that we have a facility located in the US," said Frédéric Gabriel, General Manager for Haselmeier GmbH. “The US is only one part in our global expansion”, Gabriel added “and Haselmeier views its presence in the US as a key component of its global strategy.” In addition, Haselmeier, Inc. will seek potential relationships with organizations developing new technology and emerging opportunities in drug delivery.
The US Company will be headed by Robert J. Kilgore, who was previously Vice President of Global Marketing & Business Development for Haselmeier GmbH and has over 25 years of experience with injection technology. Haselmeier Inc. will market Haselmeier’s products and services to the pharmaceutical and biotech industry.
"Our goal is to provide the best possible support and service to customers and increase awareness of Haselmeier’s current and future self-injection platforms." said Robert Kilgore. "We want to be available and responsive to companies evaluating our technology.”
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE
Researchers Reveal How Superbug Secretes It’s ToxinNews
Monash University’s Biomedicine Discovery Institute (BDI) researchers have created the first high-resolution structure depicting a crucial part of the ‘superbug’ Pseudomonas aeruginosa. The image identifies the ‘nanomachine’ used by the highly virulent bacteria to secrete toxins, pointing the way for drug design targeting this.READ MORE
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018